Genome-Wide ChIP-seq and RNA-seq Analyses of STAT3 Target Genes in TLRs Activated Human Peripheral Blood B Cells

Area of Science:

• Immunology
• Molecular Biology
• Genetics

Background:

• Toll-like receptors (TLRs) are crucial for B-cell development and activation, with TLR7 and TLR9 signaling exhibiting complex interactions.
• Signal transducer and activator of transcription (STAT) 3 is a key transcription factor in TLR7 and TLR9 pathways, and its dysfunction is linked to immune disorders like AD-HIES.
• The genome-wide impact of STAT3 on B-cell responses to TLR stimulation remains largely uncharacterized.

Purpose of the Study:

• To elucidate the genome-wide targets and downstream pathways regulated by STAT3 in human B cells upon TLR7 and TLR9 stimulation.
• To understand how STAT3 integrates TLR7 and TLR9 signaling to modulate B-cell responses.
• To identify potential therapeutic targets for TLR-mediated immune dysregulation.

Main Methods:

• Chromatin immunoprecipitation sequencing (ChIP-seq) to identify STAT3-binding sites in B cells after TLR7 and TLR9 agonist stimulation.
• RNA sequencing (RNA-seq) to analyze gene expression changes in response to TLR7 and TLR9 activation.
• Integration of ChIP-seq and RNA-seq data to identify direct STAT3 target genes.

Main Results:

• STAT3 binds to distinct genomic regions and regulates numerous genes following TLR7 and TLR9 stimulation.
• A significant number of STAT3 target genes encode other transcription factors, suggesting complex regulatory networks.
• STAT3 directly regulates the integrin signaling pathway, potentially mediating TLR9 responses and influencing the antagonism between TLR7 and TLR9 signaling.

Conclusions:

• STAT3 plays a critical role in orchestrating B-cell responses to TLR7 and TLR9 agonists at a genome-wide level.
• The findings reveal novel STAT3-regulated genes and pathways involved in TLR signaling, offering insights into immune regulation.
• Understanding STAT3's role in TLR signaling provides a basis for developing strategies to modulate aberrant immune responses in B cells.